Abstract
Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatoryfibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.
Keywords: insulin resistance, diabetes, atherosclerosis, Advanced glycation end products, oxidative stress, nitric oxide
Current Pharmaceutical Design
Title: Pleiotropic Effects of Nifedipine on Atherosclerosis
Volume: 12 Issue: 12
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura, Katsuhiko Takenaka, Takanori Matsui and Hiroyoshi Inoue
Affiliation:
Keywords: insulin resistance, diabetes, atherosclerosis, Advanced glycation end products, oxidative stress, nitric oxide
Abstract: Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatoryfibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo, Takenaka Katsuhiko, Matsui Takanori and Inoue Hiroyoshi, Pleiotropic Effects of Nifedipine on Atherosclerosis, Current Pharmaceutical Design 2006; 12 (12) . https://dx.doi.org/10.2174/138161206776389877
DOI https://dx.doi.org/10.2174/138161206776389877 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Nitric Oxide (Guest Editor: Greg Thatcher)]
Current Topics in Medicinal Chemistry Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Current Pharmaceutical Design Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology New Advances in Atrial Fibrillation Management: The Role of Apixaban
Current Drug Targets Evaluation of Cell Tolerability of a Series of Lipoamino Acids Using Biological Membranes and a Biomembrane Model.
Current Drug Delivery Renal Heat Shock Proteins Over-Expression Due to Anabolic Androgenic Steroids Abuse
Mini-Reviews in Medicinal Chemistry Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Current Approaches to the Diagnosis of Classical form of Congenital Adrenal Hyperplasia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Blockade of Renin-Angiotensin-Aldosterone System in Hemodialysis Patients to Control Hypertension and Prevent Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design Elucidation of the Mechanisms and Molecular Targets of Qishen Yiqi Formula for the Treatment of Pulmonary Arterial Hypertension using a Bioinformatics/Network Topology-based Strategy
Combinatorial Chemistry & High Throughput Screening Cardiovascular Risk Factors and Dietary Patterns
Current Nutrition & Food Science Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews